CancerNetwork Members: Login | Register
 

 
MULTIMEDIA
IMAGES
Chronic myeloid leukemia (CML): marked leucocytosis with granulocyte left shift. Source: Paulo Mourao, Wikimedia Commons


Microscopic analysis of blood smear stained with May-Grünwald/Giemsa, from a patient with Chronic Myeloid Leukemia. Source: Dr Ramon Simon-Lopez, Wikimedia Commons

VIDEOS
Dr. Sonali Smith discusses the newest developments in the treatment of CML.


Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.
 

 
NEWS
Medical News: ASH: Major Studies on Tap for 2011 Meeting - in Meeting Coverage, ASH: Hematology from MedPage Today
www.medpagetoday.com -
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs
 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Sign up for our
Newsletters
Subscribe to our
RSS Feed

Chronic Myeloid Leukemia
 
FEATURED CONTENT
January 17, 2012
What to Order From the Prostate Cancer Treatment Menu?
These are, indeed, exciting times for patients with metastatic prostate cancer and the clinicians who care for them. More »
January 13, 2012
Continuing Good News for Chronic Myeloid Leukemia Patients
The results of the 2-year follow-up of the dasatinib DASISION phase III trial show the continued superiority of the drug compared to imatinib. The results provide further support for treatment of... More »
December 31, 2011
Acute Leukemias
Hematopoietic malignancies account for 6% to 8% of new cancers diagnosed annually. In the year 2010, an estimated 43,050 new cases of leukemia were diagnosed, and 21,840 deaths were attributable to... More »
December 20, 2011
Fluid Complications
Malignant pleural effusion complicates the care of approximately 150,000 people in the United States each year. More »
November 30, 2011
Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is the IV infusion of hematopoietic stem and progenitor cells designed to establish marrow and immune function in patients with a variety of acquired and... More »
November 10, 2011
Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including... More »
November 10, 2011
Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplastic transformation of the primitive hematopoietic stem cell. More »
October 12, 2011
Mucocutaneous Paraneoplastic Syndromes Associated With Hematologic Malignancies
Paraneoplastic pemphigus (PNP) is an autoimmune-mediated, blistering, erosive, and painful mucocutaneous disease that is diagnosed almost exclusively in patients with lymphocytic neoplasms. More »
August 19, 2011
63-year-old Male Hospitalized Following a Massive Hemorrhage
A 63-year-old male was hospitalized following a massive hemorrhage secondary to a motor vehicle accident and subsequent infection of a surgical site. Three weeks post-admittance his WBC demonstrated a... More »
July 11, 2011
Genetic Abnormalities in CLL: Prognostic Factors—or Their Own Disease?
To find a new cure for a disease, or at least to significantly prolong patient survival, requires a bit of insight and a lot of luck. More »
Showing 1 - 10 of 121 results.
Page of 13
First Previous Last
 
JOURNAL SCAN
Oncogene - Abstract of article: STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis
www.nature.com - 1/9/12
Oncogene is one of the worlds leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.
Genome Medicine | Full text | Hematopoietic stem cells, hematopoiesis and disease: lessons from the zebrafish model
genomemedicine.com - 12/29/11
The zebrafish model is rapidly gaining prominence in the study of development, hematopoiesis, and disease. The zebrafish provides distinct advantages over other vertebrate models during early embryonic development by producing transparent, externally fertilized embryos. Embryonic zebrafish are easily visualized and manipulated through microinjection, chemical treatment, and mutagenesis. These procedures have contributed to large-scale chemical, suppressor, and genetic screens to identify hematopoietic gen
British Journal of Cancer - Genetic and proteomic approaches to identify cancer drug targets
www.nature.com - 12/13/11
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independenc
Opinion: A personal note[mdash]40 years after the signing of the Cancer Act : Article : Nature Reviews Clinical Oncology
www.nature.com - 11/1/11
News and Views. Nature Reviews Clinical Oncology 8, 693-694( December 2011) |. doi. : 10.1038/nrclinonc.2011.168. Subject Categories: Medical Oncology | Targeted therapies. ... Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for
Cancer Cell International | Full text | Effect of Benzothiazole based conjugates in causing apoptosis by Regulating p53, PTEN and MAP Kinase proteins affecting miR-195a and miR-101-1
www.cancerci.com - 10/28/11
Hepatocellular carcinoma (HCC) accounts for majority of liver cancers and is the leading cause of cancer related death in Asia. Like any other cancer, HCC develops when there is a mutation to the cellular machinery that causes the cell to replicate at a higher rate and results in the loss of apoptosis. Therefore, a delicate balance between the expression of various genes involved in proliferation and apoptosis decide the ultimate fate of the cell to undergo rapid proliferation (cancer) or cell death.|Hepat

Result Pages: 1 2 3 4 5 6 Next


 
CLINICAL TRIALS
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec/Gleevec_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase - Full Text View - ClinicalTrials.
www.clinicaltrials.gov -
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Mydelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
 
MEDLINE
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Detailed Description:. OBJECTIVES:. Primary. Determine the dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic
Education Sessions for Young Relative Stem Cell Donors - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
adult acute myeloid leukemia in remission. atypical chronic myeloid leukemia, BCR-ABL1 negative. ... childhood acute myeloid leukemia in remission. childhood chronic myelogenous leukemia. chronic eosinophilic leukemia.
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Acute Myeloid Leukemia. Chronic Lymphocytic Leukemia. Chronic Myelogenous Leukemia. Study Type:. ... Leukemia, Myeloid, Acute. Leukemia, Myeloid. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Hematologic Neoplasms.
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia ( STIM). ... Leukemia. Leukemia, Myeloid. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Chronic Disease. Neoplasms by Histologic Type.
Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
serial number protocol ICSG/CML/022) in patients with Ph+ chronic myeloid leukemia ( CML) in chronic phase ( CP) previously untreated, at high Sokal risk. ... CML022. Additional relevant MeSH terms:. Leukemia. Leukemia, Myeloid. Leukemia, Myelogenous,

Result Pages: 1 2 3 4 5 6 Next




 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 
 
FROM PHYSICIANS PRACTICE
Tax Schemes Every Physician Should Avoid
Ike Devji, JD, January 31, 2012
The next 60 days marks the final push to sell physicians across the United States tax plans of both good and questionable value.
Boosting Collections at Your Medical Practice: Whose Job Is It?
P.J. Cloud-Moulds, January 28, 2012
Embrace the relationship between your billing company and your medical practice staff.
Managing Difficult Medical Practice Employees
Shelly K. Schwartz, January 27, 2012
Tips for transforming immature staff members into great employees.
Prevent Physician Distraction When Using mHealth Technology
Aubrey Westgate, January 25, 2012
As more and more physicians use handheld mobile technology in their day-to-day work, some critics are raising concerns about “distracted doctoring.”
Can That Applicant Do the Job at Your Medical Practice?
Karen Zupko, January 25, 2012
If like many communities, yours has significant numbers of non-English speaking people with whom neither you nor your staff are able to converse, your practice is at a serious disadvantage.
 
MOST POPULAR
 
COMMENTS